RecruitingNot ApplicableNCT04164173

Hyperinflation Respiratory Therapies in Cardiac Surgery Patients

Hyperinflation Respiratory Therapies in Cardiac Surgery Patients: A Randomized, Observer-Blinded, Prospective Clinical Trial


Sponsor

University of Texas Southwestern Medical Center

Enrollment

324 participants

Start Date

Jun 15, 2020

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this prospective randomized clinical trial is to evaluate three different types of hyperinflation respiratory therapies, Intermittent Positive Pressure Breathing (IPPB), Intermittent positive end expiratory pressure (EzPAP), Metaneb. Investigators will examine which hyperinflation therapy provides better lung expansion and may improve lung recovery after surgery.


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Inclusion Criteria3

  • Age 18 years and older
  • Admitted to Cardiovascular ICU (CVICU) after coronary artery bypass grafting (CABG), isolated valve repair/replacement, or CABG + valve repair/replacement
  • Cardiac surgery performed via median sternotomy

Exclusion Criteria3

  • BMI>40
  • Refusal to be consented
  • Prior or current lung transplant patients

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEEzPAP

Patient will receive 10 min EzPAP 4 times daily

DEVICEMetaneb

Patient will receive 10 min Metaneb 4 times daily

DEVICEIntermittent Positive Pressure Breathing (IPPB)

Patient will receive 10 min IPPB 4 times daily


Locations(1)

UT Southwestern Clements University Hospital

Dallas, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04164173


Related Trials